RTI Surgical, Inc. (RTIX)
(Delayed Data from NSDQ)
$5.52 USD
+0.20 (3.76%)
Updated May 3, 2019 04:00 PM ET
After-Market: $5.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.52 USD
+0.20 (3.76%)
Updated May 3, 2019 04:00 PM ET
After-Market: $5.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Company News for Jan 15, 2020
by Zacks Equity Research
Companies in the news are: WFC, DAL, RTIX, SLGG
RTI Surgical Buys Paradigm Spine, Adds Coflex to Portfolio
by Zacks Equity Research
RTI Surgical's (RTIX) acquisition of Paradigm Spine aligns with the former's goal of expanding its spine portfolio.
RTI Surgical Gains From HealthPartners' Nod for SI Surgery
by Zacks Equity Research
RTI Surgical's (RTIX) minimally invasive SImmetry System sees lucrative market prospects for the stock's growth.
RTI Surgical (RTIX) Q3 Earnings Top Estimates
by Zacks Equity Research
RTI Surgical (RTIX) delivered earnings and revenue surprises of 50.00% and -1.46%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
RTI Surgical (RTIX) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
RTI Surgical (RTIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RTI Surgical's (RTIX) TETRAfuse Wins Spine Technology Award
by Zacks Equity Research
RTI Surgical (RTIX) to receive the Spine Technology Award from Orthopedics This Week at the NASS 33rd Annual Meeting in Los Angeles.
Is RTI Surgical (RTIX) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
CVS Health (CVS) PBM Strengthens, Aetna Deal Shows Promise
by Zacks Equity Research
A robust 2019 PBM selling season is a tailwind for CVS Health (CVS). Additionally, the company's milestone acquisition of Aetna might alter the whole healthcare landscape in the United States.
Pacific Biosciences (PACB) Up as VGP Picks Flagship Sequel
by Zacks Equity Research
Pacific Biosciences (PACB) sees a slew of developments in its coveted SMRT Sequel platform.
Is RTI Surgical (RTIX) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
RTI Surgical Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
RTI Surgical has been struggling lately, but the selling pressure may be coming to an end soon.
RTIX or ABMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
RTIX vs. ABMD: Which Stock Is the Better Value Option?
Is RTI Surgical (RTIX) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
RTIX or INGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
RTIX vs. INGN: Which Stock Is the Better Value Option?
RTI Surgical (RTIX) to Acquire Zyga, Improve Spine Surgeries
by Zacks Equity Research
RTI Surgical (RTIX) to integrate Zyga's SImmetry Sacroiliac Joint Fusion System to diversify Spine franchise.
NuVasive's TLX Interbody System Gets Expanded FDA Approval
by Zacks Equity Research
NuVasive (NUVA) leaves no stone unturned to cash in on the rapidly-evolving spine market.
NuVasive Acquires Vetera Spine, Grows With Spinal Hardware
by Zacks Equity Research
NuVasive aims to market and distribute Vetera Spine's FDA-approved COHERE Cervical and COALESCETM Lumbar Interbody fusion devices in the United States.
RTI Surgical at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of RTI Surgical, Inc. (RTIX), based in Alachua, FL, scaled a new 52-week high of $6.00 on Jul 10, eventually closing a bit lower at $5.65.
Zacks.com featured highlights: Sandy Spring Bancorp, Gray Television, First American Financial, RTI Surgical and International Seaways
by Zacks Equity Research
Zacks.com featured highlights: Sandy Spring Bancorp, Gray Television, First American Financial, RTI Surgical and International Seaways
5 Stocks to Gain on New Analyst Coverage
by Zacks Equity Research
Initiation of coverage by analysts offers critical information on a stock which is of great value to investors. We have selected five stocks that have seen increased analyst coverage over the last few weeks.
RTI Surgical Now Part of US-Based Manufacturing Initiative
by Zacks Equity Research
RTI Surgical, Inc. (RTIX) recently announced that it is now part of a US public-private Manufacturing initiative, the Advanced Regenerative Manufacturing Institute.
RTI Surgical (RTIX) Jumps: Stock Moves Up 5.2% in Session
by Zacks Equity Research
RTI Surgical, Inc. (RTIX) moved big last session, as its shares rose over 5% on the day.
Accelerate Diagnostics (AXDX) Looks Good: Stock Up 7.5%
by Zacks Equity Research
Accelerate Diagnostics, Inc. (AXDX) rose above 7% in the last trading session.